Drug Profile
Research programme: microtubule modulators - Biogen
Alternative Names: Peloruside; Peloruside A; RTA 301Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator University of Texas Southwestern Medical Center; Victoria University of Wellington
- Developer Biogen
- Class Heterocyclic bicyclo compounds; Lactones
- Mechanism of Action Mitosis inhibitors; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Sep 2023 Reata Pharmaceuticals has been acquired and merged into Biogen
- 07 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events and the Cancer pharmacodynamics sections
- 27 Apr 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section